Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27184002 | 0.84 | SMN1; SMN2 (0.53) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL77454 | 0.83 | NPC1 (0.65) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL27184188 | 0.82 | SMN1; SMN2 (0.53) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL29311904 | 0.81 | MAPK1 (0.52) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL27183969 | 0.79 | KMT2A (0.53) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL3791723 | 0.78 | KMT2A (0.53) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL27183848 | 0.78 | MAPK1 (0.49) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL7677063 | 0.77 | KMT2A (0.76) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL27183739 | 0.77 | SMN1; SMN2 (0.48) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL31341018 | 0.76 | KMT2A (0.63) | MEN1KMT2AGAAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| EP-4543443-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024002270-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | MEN1 3234/4885KMT2A 3181/4885GAA 249/4885 |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | PHKA1, PHKA2, PHKG1 | MEN1 2806/4885KMT2A 2978/4885GAA 1065/4885 |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | PHKA1, PHKA2, PHKG1 | MEN1 3169/4885KMT2A 2582/4885GAA 438/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | MEN1 3121/4885KMT2A 2191/4885GAA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.